Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
Status:
Recruiting
Trial end date:
2022-07-05
Target enrollment:
Participant gender:
Summary
To evaluate the safety of [64Cu] Macrin and its whole-body distribution, metabolism,
pharmacokinetics, and radiation burden in healthy volunteers. To detect [64Cu]-Macrin
accumulation in sites of disease in subjects with cancer, sarcoidosis or myocardial infarct.